ImmunoPrecise Antibodies (IPA) (NASDAQ:IPA) announced new benchmarking results validating the accuracy and utility of its in silico epitope mapping application—part of the LENSai platform, which delivers x-ray-level epitope mapping insights in hours.
According to IPA, the results represent advancement in antibody discovery, where high failure rates and costly, time-intensive experiments remain common industry challenges. The LENSai platform matched the performance of x-ray crystallography—the industry’s gold standard, which is precise but slow and expensive.
In a statement, Dr. Jennifer Bath, CEO 0f IPA, commented, “In an industry where 95% of drug candidates fall before reaching the clinic, accelerating decisions earlier in the discovery pipeline isn’t a luxury—it’s a necessity. With LENSai, we’re demonstrating that AI is designed to deliver accurate, scalable, and human-relevant biological predictions that were previously only accessible through months of experimental work.”
